(S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate - CAS 1025796-31-9

(S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate - CAS 1025796-31-9 Catalog number: BADC-00510

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

(S)-Di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate is a PEG linker for antibody-drug-conjugation (ADC).

Category
ADCs Linker
Product Name
(S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate
CAS
1025796-31-9
Catalog Number
BADC-00510
Molecular Formula
C24H45N3O7
Molecular Weight
487.63
Purity
95%
(S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate

Ordering Information

Catalog Number Size Price Quantity
BADC-00510 100 mg $199 Inquiry
Description
(S)-Di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate is a PEG linker for antibody-drug-conjugation (ADC).
Synonyms
1,5-Bis(1,1-dimethylethyl) N-[[[(1S)-5-amino-1-[(1,1-dimethylethoxy)carbonyl]pentyl]amino]carbonyl]-L-glutamate
IUPAC Name
ditert-butyl (2S)-2-[[(2S)-6-amino-1-[(2-methylpropan-2-yl)oxy]-1-oxohexan-2-yl]carbamoylamino]pentanedioate
Canonical SMILES
CC(C)(C)OC(=O)CCC(C(=O)OC(C)(C)C)NC(=O)NC(CCCCN)C(=O)OC(C)(C)C
InChI
InChI=1S/C24H45N3O7/c1-22(2,3)32-18(28)14-13-17(20(30)34-24(7,8)9)27-21(31)26-16(12-10-11-15-25)19(29)33-23(4,5)6/h16-17H,10-15,25H2,1-9H3,(H2,26,27,31)/t16-,17-/m0/s1
InChIKey
IXWXFSGSTGXUFO-IRXDYDNUSA-N
Appearance
solid
Shipping
Room temperature
Storage
2-8°C

(S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate, a sophisticated synthetic compound with potential in pharmaceutical and biochemical realms, presents diverse applications. Embracing high perplexity and burstiness, here are four key applications:

Peptide Synthesis: Serving as an intermediary in complex peptide synthesis, this compound safeguards specific functional groups during peptide chain assembly, ensuring precise reactions with elevated selectivity and yield. Its robust stability across various reaction conditions renders it invaluable in generating high-purity peptides for both research and therapeutic pursuits.

Drug Development: Positioned at the forefront of pharmaceutical innovation, (S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate emerges as a versatile contributor to novel drug development. Its distinctive structure serves as a foundational element for molecules potentially harboring biological activity, such as enzyme inhibitors or receptor agonists. Researchers harness this compound to explore evolving drug candidates through strategic modifications of functional groups, fostering enhanced efficacy and reduced toxicity.

Proteomics Research: In the dynamic realm of proteomics, this compound plays a pivotal role in chemical protein modification and labeling. Its reactive groups facilitate the attachment of diverse tags or probes to proteins, streamlining their identification and analysis via cutting-edge techniques like mass spectrometry or fluorescence methods. This application proves instrumental in deciphering protein-protein interactions and unraveling the proteome within varied biological milieus.

Bioconjugation: Unlocking a realm of possibilities, (S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate finds purpose in bioconjugation methodologies, seamlessly linking biomolecules such as peptides, proteins, and nucleic acids to other molecular entities. This process forms the cornerstone for crafting conjugates tailored for targeted drug delivery, diagnostic imaging, or therapeutic interventions. The compound's adaptability empowers the creation of stable, functional bioconjugates tailored to diverse biomedical exigencies, propelling advancements in healthcare.

1.Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
zabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG.
PURPOSE:Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [(18)F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer.PROCEDURES:Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM.RESULTS:No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [(18)F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi).CONCLUSIONS:[(18)F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [(18)F]DCFPyL is similar to that from other PET radiotracers.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket